Ravulizumab Medication Information

Get detailed information on Ravulizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.

The updated prescription information on Ravulizumab provides an overview of possible side effects, precautions, warnings, and storage tips.

You'll also find brand names used in india and internationally, along with pricing details. For further clarification, consult your healthcare provider.

Generic Name : Ravulizumab

Pronunciation : RAV-yoo-LIZ-yoo-mab

Trade Names/Brand Names of Ravulizumab

India :

Ultomiris

Overview of Ravulizumab

Ravulizumab is a type of monoclonal antibody used to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH is a rare life-threatening disease of the blood in which there is destruction of red blood cells by the complement (part of the body's innate immune system).

Why is Ravulizumab Prescribed? (Indications)

Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria

When should Ravulizumab not be taken? (Contraindications)

It should not be used in patients with unresolved meningitis

What is the dosage of Ravulizumab?

Ravulizumab is available as an Injection.
Dose is 300 mg/30mL (10 mg/mL).

How should Ravulizumab be taken?

Ravulizumab is given as an intravenous infusion.
It's dose is based on body weight.

Missed a Dose?

If a Ravulizumab infusion is missed, call your doctor right away.

What are the warnings and precautions for Ravulizumab?

•Life-threatening meningococcal infections could occur in patients treated with Ravulizumab. They should be addressed immediately.

• Follow the recommendations of the current Advisory Committee on Immunization Practices (ACIP) for meningococcal vaccination among patients with complement deficiencies two weeks before usage of ravulizumab.

• Ravulizumab is available under Risk Evaluation and Mitigation Strategy (REMS). Healthcare professionals who prescribe ravulizumab must enroll in the ravulizumab REMS.

• Caution is needed while prescribing ravulizumab to patients with systemic infections.

• After stopping the treatment, monitor for signs and symptoms of hemolysis for 16 weeks.

• These Signs include decrease in haemoglobin, or re-appearance of fatigue, hemoglobinuria, abdominal pain, breathing difficulties, thrombosis (blood clotting), dysphagia (painful swallowing), or erectile dysfunction.

What are the side effects of Ravulizumab?

Commonest side effects of Ravulizumab are upper respiratory infection and headache.
Other side effects:
Gastrointestinal: Diarrhea, Nausea, Abdominal pain
Nervous system: Dizziness
Musculoskeletal: Pain in extremities(feet, legs, fingers), arthralgia(joint pain)
General disorders: Pyrexia(fever)
Infusion-related: Low back pain, drop in blood pressure and infusion-related pain. Interrupt the infusion and give supportive measures in this case.

What are the other precautions for Ravulizumab?

Tell your physician if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed. You should not breast-feed during the treatment and for 8 months after the last dose of ravulizumab.